RCGP statement on partnership with Novo Nordisk
Publication date: 27 March 2023
The RCGP has ended its partnership with Novo Nordisk following the ABPI's decision to suspend the company for breaches of its code of practice. All outstanding funds paid to the College by Novo Nordisk will be returned.
The College works with a variety of partners, including those in the pharmaceutical sector, to develop educational resources to support GPs and other healthcare professionals deliver high-quality patient care.
Editorial control of all content always sits with the RCGP and is completely independent.
The College follows a strict sponsorship policy when working with partners, which includes that any partnership arrangements should comply with the ABPI Code of Practice.
Novo Nordisk were funding a number of existing projects, which have now been cancelled. Several educational resources previously funded by Novo Nordisk and compliant with the ABPI Code of Practice will remain but are currently undergoing review.
RCGP Press office: 020 3188 7633
Notes to editor
The Royal College of General Practitioners is a network of more than 54,000 family doctors working to improve care for patients. We work to encourage and maintain the highest standards of general medical practice and act as the voice of GPs on education, training, research and clinical standards.